Amanda R. McCullough

Amanda R. McCullough

Top Cited Scholar 2023
Auto-generated profile, based on publicly available information

Amanda R. McCullough

Bond University; Centre for Research in Evidence-Based Practice (CREBP); Gold Coast Queensland Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
AMA. R. McCullough
A. R. McCullough
SPS. Parekh
S. Parekh
JRJ. Rathbone
J. Rathbone
CMC. B. Del Mar
C. B. Del Mar
THT. C. Hoffmann
T. C. Hoffmann
The objective of this study was to systematically review quantitative and qualitative studies on the public's knowledge and beliefs about antibiotic resistance. We searched four databases to July 2014, with no language or study design restrictions. Two reviewers independently extracted data. We calculated the median (IQR) of the proportion of participants who agreed with each statement and synthesized qualitative data by identifying emergent themes. Of 3537 articles screened, 54 studies (41 quantitative, 3 mixed methods and 10 qualitative) were included (55 225 participants). Most studied adults (50; 93% studies) and were conducted in Europe (23; 43%), Asia (14; 26%) or North America (12; 22%). Some participants [median 70% (IQR 50%–84%); n = 8 studies] had heard of antibiotic resistance, but most [median 88% (IQR 86%–89%); n = 2 studies] believed it referred to changes in the human body. Many believed excessive antibiotic use [median 70% (IQR 59%–77%); n = 11 studies] and not completing antibiotic courses [median 62% (IQR 47%–77%); n = 8 studies] caused resistance. Most participants nominated reducing antibiotic use [median 74% (IQR 72%–85%); n = 4 studies] and discussing antibiotic resistance with their clinician (84%, n = 1 study) as strategies to reduce resistance. Qualitative data supported these findings and additionally identified that: participants believed they were at low risk from antibiotic resistance participants; largely attributed its development to the actions of others; and strategies to minimize resistance should be primarily aimed at clinicians. The public have an incomplete understanding of antibiotic resistance and misperceptions about it and its causes and do not believe they contribute to its development. These data can be used to inform interventions to change the public's beliefs about how they can contribute to tackling this global issue.

7 September 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
STSarah Tonkin-Crine
Sarah Tonkin-Crine
PTPui San Tan
Pui San Tan
OHOliver Van Hecke
Oliver Van Hecke
KWKay Wang
Kay Wang
NRNia W Roberts
Nia W Roberts
CMChris B Del Mar
Chris B Del Mar

17 July 2017 in Medical Journal of Australia
Verified
Journal Article
Closed access
AMAmanda R McCullough
Amanda R McCullough
APAllan J Pollack
Allan J Pollack
MHMalene Plejdrup Hansen
Malene Plejdrup Hansen
PGPaul P Glasziou
Paul P Glasziou
DLDavid Fm Looke
David Fm Looke
CMChristopher B Del Mar
Christopher B Del Mar
Antibiotic prescribing in Australian general practice could be substantially reduced

20 June 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
AMA. R. McCullough
A. R. McCullough
JRJ. Rathbone
J. Rathbone
SPS. Parekh
S. Parekh
THT. C. Hoffmann
T. C. Hoffmann
CMC. B. Del Mar
C. B. Del Mar
To systematically review clinicians' knowledge and beliefs about the importance and causes of antibiotic resistance, and strategies to reduce resistance. Four databases were searched (until July 2014), without restrictions on language, setting or study design. Fixed responses (from surveys) were grouped into categories. The proportion of participants who agreed with each category was expressed as median, percentage and IQR. Qualitative data were coded into emergent themes. Quantitative categories and qualitative themes were grouped into four overarching categories that emerged from the data. There were 57 included studies (38 quantitative, 14 qualitative, 5 mixed methods) of 11 593 clinicians. Most clinicians (69%, IQR 63%–72%, n = 5 studies) had heard of antibiotic resistance and 98% (IQR 93%–99%, n = 5 studies) believed it was serious. The proportion who believed it was a problem for their practice (67%, IQR 65%–74%, n = 13 studies) was smaller than the proportion who believed it was a problem globally (89%, IQR 85%–97%, n = 5 studies) or nationally (92%, IQR 88%–95%, n = 21 studies). Most believed excessive antibiotic use (97%, IQR 91%–98%, n = 12 studies) and patient non-adherence (90%, IQR 82%–92%, n = 7 studies) caused resistance. Most knew of strategies to reduce resistance (e.g. clinician education, 90%, IQR 85%–96%, n = 7 studies). Qualitative findings support these data: they attributed responsibility for antibiotic resistance to patients, other countries and healthcare settings; resistance was considered a low priority and a distant consequence of antibiotic prescribing. Clinicians believe antibiotic resistance is a serious problem, but think it is caused by others. This needs to be accommodated in interventions to reduce antibiotic resistance.

1 July 2014 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
AMAmanda R McCullough
Amanda R McCullough
MTMichael M Tunney
Michael M Tunney
AQAlexandra L Quittner
Alexandra L Quittner
SEStuart Elborn
Stuart Elborn
JBJudy M Bradley
Judy M Bradley
CHCarmel M Hughes
Carmel M Hughes
We aimed to determine adherence to inhaled antibiotics, other respiratory medicines and airway clearance and to determine the association between adherence to these treatments and health outcomes (pulmonary exacerbations, lung function and Quality of Life Questionnaire-Bronchiectasis [QOL-B]) in bronchiectasis after 12 months. Patients with bronchiectasis prescribed inhaled antibiotics for Pseudomonas aeruginosa infection were recruited into a one-year study. Participants were categorised as “adherent” to medication (medication possession ratio ≥80% using prescription data) or airway clearance (score ≥80% in the Modified Self-Reported Medication-Taking Scale). Pulmonary exacerbations were defined as treatment with a new course of oral or intravenous antibiotics over the one-year study. Spirometry and QOL-B were completed at baseline and 12 months. Associations between adherence to treatment and pulmonary exacerbations, lung function and QOL-B were determined by regression analyses. Seventy-five participants were recruited. Thirty-five (53%), 39 (53%) and 31 (41%) participants were adherent to inhaled antibiotics, other respiratory medicines, and airway clearance, respectively. Twelve (16%) participants were adherent to all treatments. Participants who were adherent to inhaled antibiotics had significantly fewer exacerbations compared to non-adherent participants (2.6 vs 4, p = 0.00) and adherence to inhaled antibiotics was independently associated with having fewer pulmonary exacerbations (regression co-efficient = -0.51, 95% CI [-0.81,-0.21], p < 0.001). Adherence to airway clearance was associated with lower QOL-B Treatment Burden (regression co-efficient = -15.46, 95% CI [-26.54, -4.37], p < 0.01) and Respiratory Symptoms domain scores (regression co-efficient = -10.77, 95% CI [-21.45; -0.09], p < 0.05). There were no associations between adherence to other respiratory medicines and any of the outcomes tested. Adherence to treatment was not associated with FEV1 % predicted. Treatment adherence is low in bronchiectasis and affects important health outcomes including pulmonary exacerbations. Adherence should be measured as part of bronchiectasis management and future research should evaluate bronchiectasis-specific adherence strategies.

13 February 2017 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
LSLucy Sargent
Lucy Sargent
AMAmanda McCullough
Amanda McCullough
CMChris Del Mar
Chris Del Mar
JLJohn Lowe
John Lowe
Delayed antibiotic prescribing reduces antibiotic use for acute respiratory infections in trials in general practice, but the uptake in clinical practice is low. The aim of the study was to identify facilitators and barriers to general practitioners’ (GPs’) use of delayed prescribing and to gain pharmacists’ and the public’s views about delayed prescribing in Australia. This study used the Theoretical Domains Framework and the Behaviour Change Wheel to explore facilitators and barriers to delayed prescribing in Australia. Forty-three semi-structured, face-to-face interviews with general practitioners, pharmacists and patients were conducted. Responses were coded into domains of the Theoretical Domains Framework, and specific criteria from the Behaviour Change Wheel were used to identify which domains were relevant to increasing the use of delayed prescribing by GPs. The interviews revealed nine key domains that influence GPs’ use of delayed prescribing: knowledge; cognitive and interpersonal skills; memory, attention and decision-making processes; optimism; beliefs about consequences; intentions; goals; emotion; and social influences: GPs knew about delayed prescribing; however, they did not use it consistently, preferring to bring patients back for review and only using it with patients in a highly selective way. Pharmacists would support GPs and the public in delayed prescribing but would fill the prescription if people insisted. The public said they would delay taking their antibiotics if asked by their GP and given the right information on managing symptoms and when to take antibiotics. Using a theory-driven approach, we identified nine key domains that influence GPs’ willingness to provide a delayed prescription to patients with an acute respiratory infection presenting to general practice. These data can be used to develop a structured intervention to change this behaviour and thus reduce antibiotic use for acute respiratory infections in general practice.